Stock Events

Eledon Pharmaceuticals 

$3.09
13
+$0.06+2.15% Today

Statistics

Day High
-
Day Low
-
52W High
3.29
52W Low
1.07
Volume
358,815
Avg. Volume
335,622
Mkt Cap
118.79M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

28MarConfirmed
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.75
-0.61
-0.46
-0.32
Expected EPS
-0.39
Actual EPS
-0.32

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELDN. It's not an investment recommendation.
Alphabet
63772
GOOGL
Apple
56875
AAPL
Microsoft
52480
MSFT
Amazon
48580
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap33.57B
Biogen focuses on neurodegenerative diseases, directly competing with Eledon's focus on neurological conditions.
Regenxbio
RGNX
Mkt Cap787.6M
REGENXBIO is involved in gene therapy for neurodegenerative diseases, overlapping with Eledon's therapeutic areas.
Ionis Pharmaceuticals
IONS
Mkt Cap5.45B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the same space as Eledon's focus on treatments for autoimmune diseases.
Sage Therapeutics
SAGE
Mkt Cap704.13M
Sage Therapeutics targets brain health disorders, including treatments for conditions that Eledon Pharmaceuticals also aims to address.
Alnylam Pharmaceuticals
ALNY
Mkt Cap18.9B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, some of which are in direct competition with Eledon's focus areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap114.89B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, including cystic fibrosis, which could overlap with Eledon's target disease areas.
Novartis
NVS
Mkt Cap224.62B
Novartis offers a broad range of healthcare solutions, including treatments for neurological conditions that compete with Eledon's portfolio.
AMGEN
AMGN
Mkt Cap167.62B
Amgen focuses on human therapeutics, including treatments for neurological and autoimmune diseases, competing with Eledon's research areas.
Gilead Sciences
GILD
Mkt Cap84.37B
Gilead Sciences, known for antiviral drugs, also explores treatments in areas that could compete with Eledon's focus on autoimmune diseases.
Pfizer
PFE
Mkt Cap162.29B
Pfizer has a diverse portfolio, including drugs for neurological and autoimmune disorders, directly competing with Eledon Pharmaceuticals.

Analyst Ratings

16$Average Price Target
The highest estimate is $16.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Show more...
CEO
Gregory Flesher
Employees
20
Country
US
ISIN
US28617K1016
WKN
000A2QL00

Listings

F
DE
2TK.F
XNAS
US
ELDN